The pharmaceutical and biotechnology company will market 25mg, 50mg, 100mg, 200mg and 300mg extended release tablets of Lamictal XR, under its generic name Lamotrigine. Lamictal XR is marketed in the US by Glaxo SmithKline.

            With its own Lamotrigine tablets, Wockhardt intends to be one of the first generic versions of the product to reach the market and it will be launched immediately.

            Dr Habil Khorakiwala, founder, chairman and group chief executive of the company, said: "We are continuing our rapid momentum of 2012 in the New Year with this approval of Lamotrigine extended release tablets.

            "This is the sixth product drug delivery technology that has received US Food and Drug Administration approval in the last five months, a continuing testimony to the R&D capabilities of Wockhardt."